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 Der Editor, 
  Bullous pemphigoid (BP) is increasingly reported with immune checkpoint inhibitors 
(ICI) directed against programmed cell death protein-1 (PD-1) (Lopez, 2018) [1]. Molina et al 
recently report about clinical difference between ICI induced BP and idiopathic BP (Molina, 2020) 
[2]. We wish to report an atypical case of BP-like eruption after sun exposure under nivolumab. 
A 70-year-old man presented an acute exanthema of the upper and lower limbs with blisters on 
the legs. His medical history was notable for choroidal melanoma of the left eye and right-sided 
renal clear-cell carcinoma (RCC) both diagnosed and treated in 2015. Two years later, RCC 
metastases prompted to start tyrosine kinase inhibitor (TKI) sunitinib, that was discontinued after 
six months due to progression. Nivolumab was initiated (3 mg/kg eow). The patient reported self-
limiting oral blisters after each of the first 4 infusions. Before the 12th infusion, he developed an 
acute itchy rash on the soles that extended rapidly to the lower and upper limbs and the back. 
Upon examination, the patient displayed a dusky red exanthema mostly on sun-exposed areas 
(forearms, hands, palms and lower limbs, Fig. 1) with tense blisters on the legs and a slight 
eruption on the trunk. The face was unaffected. The patient was an avid golfer and acknowledged 
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playing quite much during the summer. The rest of the examination, including mucosae, was 
unremarkable. Laboratory findings showed hypereosinophilia (800/mm3) and elevated CRP (50 
mg/L). Antinuclear antibodies, soluble antigens antibodies, indirect immunofluorescence test and 
ELISA BP180 were negative. Histology showed a sub- and intra-epidermal blister containing 
eosinophils and an eosinophil rich infiltration in the dermis without sunburn cells. Direct 
immunofluorescence on lesional skin revealed junctional C3 deposition without immunoglobulins.  
Improvement of the skin lesions was rapid under oral prednisolone (starting dose 1 mg/kg/day) 
and clobetasol propionate ointment. Nivolumab was withdrawn.  He presented at follow up visit 
with only residual pigmentation. After three months of follow-up, the rash had not relapsed. 
Because of progression of RCC, cabozantinib, a multi-TKI, was initiated as a third line treatment. 
We report here a case of PB-like dermatosis, mainly restricted to photoexposed areas during 
nivolumab therapy. To our knowledge, PD-1 inhibitors have never been associated with increased 
photosensitivity or phototoxicity. However, BP has been described within 6 to 8 months from 
initiation [1]. Arguments that favor such hypothesis in our case are: 1) compatible delay of onset 
after nivolumab initiation (Lopez, 2018), 2) transient hypereosinophilia, histology and DIF features, 
3) histology did not support simple severe sunburn, 4) ICI induced BP may exhibit atypical features 
(Molina, 2020), 5) lack of other BP-inducing drugs, and 6) lack of relapse after nivolumab 
withdrawal. BP has been reported after UVB or UVA exposure (George, 1996) and sunburn (Lee, 
1992). In our patient, BP may be the consequence of intense sun exposure. UV light could have 
induced the localized exposure of BP antigens through the local production and release of 
inflammatory mediators and local damage (Lee, 1992). The patient may have had a limited oral BP 
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induced by nivolumab that went unnoticed until intense sun exposure. Photo-tests with a new DIF 
would have been of interest. However, we felt untimely to perform such tests now as nivolumab 
was withdrawn and a new TKI was initiated.   
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Figure 1. Clinical presentation. (a) Dusky red exanthema of the upper limbs and legs restricted to 
sun-exposed areas. (b and c) Close-up view of the legs with blisters.  
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